Research programme: antibody-drug conjugates - HC Biopharma
Latest Information Update: 27 Aug 2024
At a glance
- Originator HC Biopharma
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours; Triple negative breast cancer
Most Recent Events
- 02 Aug 2024 Early research in Solid tumours in Hong Kong (Parenteral) (HC Biopharma Pipeline, August 2024)
- 02 Aug 2024 Early research in Triple-negative-breast-cancer in Hong Kong (Parenteral) (HC Biopharma Pipeline, August 2024)